A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol in Patients With...
SchizophreniaPsychotic DisorderThe purpose of the study is to evaluate the effectiveness and safety of different doses of risperidone (an antipsychotic medication) compared with a fixed 10-mg dose of a standard antipsychotic, haloperidol, in patients with chronic schizophrenia.
Health Care Management and Rehabilitation Skills Training for Treating Serious Mental Illness in...
SchizophreniaSchizoaffective Disorder2 moreThis study will evaluate the effectiveness of a health management and supported rehabilitation intervention in treating serious mental illnesses in older people.
Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
SchizophreniaThis study will determine the effectiveness of clozapine versus olanzapine in treating people with schizophrenia that has not improved with treatment.
An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With...
Chronic SchizophreniaThe purpose of this study is to see if galantamine is an effective agent for the treatment of the cognitive abnormalities, negative symptoms, and /or behavioral impairments seen in schizophrenia.
Janssen - Glucose Regulation/Risp/Olanz
SchizophreniaType 2 Diabetes MellitusAbnormalities in peripheral glucose regulation and type 2 diabetes can occur more commonly in individuals with schizophrenia than in healthy subjects or in other psychiatric conditions. Antipsychotic treatment may contribute significantly to abnormalities in glucose regulation. Hyperglycemia can contribute to long-term cardiovascular disease risk that may already be increased in patients with schizophrenia due to higher rates of smoking, sedentary life style, obesity and under-treated hypertension and dyslipidemia. This project will characterize the effects on glucose control of the two most commonly prescribed newer antipsychotic medications, risperidone and olanzapine, in patients with schizophrenia. This proposal specifically hypothesizes that olanzapine treatment will be associated with decreases in insulin sensitivity (SI), without effects on insulin secretion. Treatment-related effects on glucose effectiveness (SG) will be explored.
An Efficacy and Safety Study of 3 Fixed Doses of JNJ-37822681 in Participants With Schizophrenia...
SchizophreniaThe purpose of this study is to evaluate the efficacy and safety of 3 fixed doses of JNJ-37822681 compared with placebo (an inactive substance that is compared with a drug to test if the drug has a real effect in a clinical trial) after 6 weeks treatment and olanzapine after 12 weeks treatment in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self).
Effect of High-Dose B-Complex Vitamins on the Symptoms of Schizophrenia
SchizophreniaSchizoaffective DisorderThe purpose of this study is to determine whether individuals with schizophrenia who will take a high dose of the B-vitamins folate, B12 and pyridoxine, may experience improvement in their symptoms.
Study Evaluating RGH-188 in the Treatment of Patients With Schizophrenia
SchizophreniaThis is a study designed to evalute the safety and efficacy of RGH-188 in the treatment of acute schizophrenia. This study will be 10 weeks in duration; 6 weeks double-blind treatment, and 4 weeks safety follow-up. All patients meeting the eligibility criteria will be randomized to one of the three treatment groups--one of two doses of RGH-188 or placebo
CATIE- Schizophrenia Trial
SchizophreniaThe CATIE Schizophrenia Trial is part of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project. The schizophrenia trial is being conducted to determine the long-term effects and usefulness of antipsychotic medications in persons with schizophrenia. It is designed for people with schizophrenia who may benefit from a medication change. The study involves the newer atypical antipsychotics (olanzapine, quetiapine, risperidone, clozapine, and ziprasidone)and the typical antipsychotics (perphenazine and fluphenazine decanoate). All participants will receive an initial comprehensive medical and psychiatric evaluation and will be closely followed throughout the study. For most participants the study will last up to 18 months. Everyone in the study will be offered an educational program about schizophrenia and family members will be encouraged to participate.
A Multi-Site Study of Strategies for Implementing Schizophrenia Guidelines
SchizophreniaSchizophrenia, a chronic psychiatric disorder, is the second most frequent VA discharge diagnosis. Medication management practices for schizophrenia often are not guideline-concordant and place patients at risk for adverse outcomes. This project tests a new strategy to standard implementation for VHA Schizophrenia Guidelines.